ABC57
One Notre Dame team is facing a different opponent--allergies
September 24, 2016
“ What we are trying to do is understand the allergy and the allergens very specifically at the molecular level so that we can design inhibitors that will selectively inhibit only the molecules, the immune components that are responsible for the allergy response,” said Notre Dame professor Basar Bilgicer.
Fighting to Cure Food Allergies
September 14, 2016
Professor Basar Bilgicer hopes to make allergies, and the accompanying anxiety and trauma, a thing of the past.
Synergistic Dual Drug Liposomes in Multiple Myeloma
July 05, 2016
Synergistic Dual Drug Liposomes in Multiple Myeloma
Ashley et al. Page 1452
Nanoparticular drug delivery formulations typically provide a significant advantage over the free drug alternatives. To investigate the advantages of a dual drug–loaded combination nanoparticular delivery system in multiple myeloma, Ashley and colleagues designed, synthesized, and evaluated carfilzomib and doxorubicin dual-loaded combination nanoparticles at their synergistic ratio. The dual drug–loaded nanoparticles exhibited synergy in vitro and delivered considerably higher efficacy in inhibiting tumor growth in vivo compared with the free drug combination, while simultaneously reducing systemic toxicity. These results indicate utilizing nanoparticles as drug delivery vehicles for combinatorial therapeutics can have a significant impact on patient outcomes.
Inside Indiana Business
Student Startup Builds ‘Bubbles’ to Deliver Cancer Drugs
May 26, 2016
A student-run startup at the University of Notre Dame is generating buzz among pharmaceutical companies searching for better ways to deliver cancer-fighting drugs. Certus Therapeutics, which recently captured the top prize at the university’s annual McCloskey Business Plan Competition, says its technology could greatly reduce the toxic effects of chemotherapy and other cancer treatments. The young company hasn’t discovered a drug, but rather, a novel delivery method for existing medications that could prevent cancer patients from feeling even sicker.
South Bend Tribune
Cancer treatment system wins Notre Dame contest
February 26, 2016
The nanoparticle technology underlying Certus’ Lypos platform was developed by Basar Bilgicer, an associate professor of chemical and biomolecular engineering.